The GLP-1/GIP incretins are no different: from their discovery nearly 40 years ago, to their recent FDA approval(s) in obesity, we have walked through the story of how this class of medicines has emerged and developed over time
WHO Decision Recognizing Obesity as a Disease Treatable with GLP-1 Drugs Is Big Deal, says BU Endocrinologist New guidelines will help reduce stigma around weight management, Ivania Rizo says WHO Decision Recognizing Obesity as a Disease Treatable with GLP-1 Drugs Is Big Deal, says BU Endocrinologist New guidelines will help reduce stigma around weight management, Ivania Rizo says The World Health Organizations new guidelines recognizing obesity as a disease and suggesting that GLP-1 drugs be part of long-term treatment could have wide-ranging benefits, says Ivania Rizo, a Boston University endocrinologist whose research interests center on obesity, diabetes, and metabolic disorders
Carvalho AF, Sharma MS, Brunoni AR, et al
AOD 9604 has minimal reported side effects due to its targeted action
They are prepared by licensed compounding pharmacies using ingredients sourced from FDA-regulated suppliers and dispensed per individual prescriptions
Patients with type 2 diabetes who need to control their blood sugar levels
